His laboratory has focused both on understanding the molecular pathology of prostate cancer, as well as, clinical and translational research studies to analytically validate and interrogate biomarker expression in clinical pathology specimens. As leader of the immunohistochemistry core in the prostate cancer SPORE and the TMA core lab at JHU, his group developed open source software tools to facilitate high throughput TMA-based biomarker validation studies. Dr. De Marzo has also collaborated with a number of investigators at JHU and elsewhere to develop predictive biomarkers for prostate cancer. He received his M.D. and Ph.D. in experimental pathology from the University of Colorado Health Sciences Center and completed a research fellowship at The Brady Urological Institute at JHU.
"I am delighted to join Predictive Biosciences and contribute to the development of its novel non-invasive molecular diagnostics technologies," said Dr. De Marzo. "The Company's approach of providing clinically actionable information through "molecular triage" is an exciting development in the emerging field of personalized medicine that could significantly improve the care of cancer patients."
"Angelo is a great addition to our management team," said Marc Schneebaum, President and CEO of Predictive Biosciences. "His distinguished reputation in the pathology and urological oncology communities, and his extensive clinical research experience, will substantially enhance our technology development and commercial strategies and operations. His focus on developing new insights into the molecular pathology of cancer should also help shape our product offerings for optimal utility to physicians and their patients."